Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 55
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Clin Exp Immunol ; 199(3): 326-336, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31660581

RESUMEN

Secretory IgA (SIgA) is a well-known mucosal-surface molecule in first-line defense against extrinsic pathogens and antigens. Its immunomodulatory and pathological roles have also been emphasized, but it is unclear whether it plays a pathological role in lung diseases. In the present study, we aimed to determine the distribution of IgA in idiopathic pulmonary fibrosis (IPF) lungs and whether IgA affects the functions of airway epithelial cells. We performed immunohistochemical analysis of lung sections from patients with IPF and found that mucus accumulated in the airspaces adjacent to the hyperplastic epithelia contained abundant SIgA. This was not true in the lungs of non-IPF subjects. An in-vitro assay revealed that SIgA bound to the surface of A549 cells and significantly promoted production of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-ß and interleukin (IL)-8, important cytokines in the pathogenesis of IPF. Among the known receptors for IgA, A549 cells expressed high levels of transferrin receptor (TfR)/CD71. Transfection experiments with siRNA targeted against TfR/CD71 followed by stimulation with SIgA suggested that TfR/CD71 may be at least partially involved in the SIgA-induced cytokine production by A549 cells. These phenomena were specific for SIgA, distinct from IgG. SIgA may modulate the progression of IPF by enhancing synthesis of VEGF, TGF-ß and IL-8.


Asunto(s)
Fibrosis Pulmonar Idiopática/inmunología , Inmunoglobulina A Secretora/inmunología , Interleucina-8/inmunología , Pulmón/inmunología , Factor de Crecimiento Transformador beta/inmunología , Factor A de Crecimiento Endotelial Vascular/inmunología , Células A549 , Anciano , Anciano de 80 o más Años , Antígenos CD/genética , Antígenos CD/inmunología , Antígenos CD/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/inmunología , Células Epiteliales/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/inmunología , Humanos , Fibrosis Pulmonar Idiopática/metabolismo , Fibrosis Pulmonar Idiopática/patología , Inmunoglobulina A Secretora/metabolismo , Inmunoglobulina A Secretora/farmacología , Interleucina-8/genética , Interleucina-8/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Masculino , Persona de Mediana Edad , Interferencia de ARN , Receptores de Transferrina/genética , Receptores de Transferrina/inmunología , Receptores de Transferrina/metabolismo , Factor de Crecimiento Transformador beta/genética , Factor de Crecimiento Transformador beta/metabolismo , Factor A de Crecimiento Endotelial Vascular/genética , Factor A de Crecimiento Endotelial Vascular/metabolismo
2.
Clin Exp Immunol ; 195(3): 287-301, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30570135

RESUMEN

Immunoglobulin (Ig)A is the most abundant immunoglobulin in humans, and in the airway mucosa secretory IgA (sIgA) plays a pivotal role in first-line defense against invading pathogens and antigens. IgA has been reported to also have pathogenic effects, including possible worsening of the prognosis of idiopathic pulmonary fibrosis (IPF). However, the precise effects of IgA on lung fibroblasts remain unclear, and we aimed to elucidate how IgA activates human lung fibroblasts. We found that sIgA, but not monomeric IgA (mIgA), induced interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production by normal human lung fibroblasts (NHLFs) at both the protein and mRNA levels. sIgA also promoted proliferation of NHLFs and collagen gel contraction comparable to with transforming growth factor (TGF)-ß, which is involved in fibrogenesis in IPF. Also, Western blot analysis and real-time quantitative polymerase chain reaction (PCR) revealed that sIgA enhanced production of α-smooth muscle actin (α-SMA) and collagen type I (Col I) by NHLFs. Flow cytometry showed that NHLFs bound sIgA, and among the known IgA receptors, NHLFs significantly expressed CD71 (transferrin receptor). Transfection of siRNA targeting CD71 partially but significantly suppressed cytokine production by NHLFs co-cultured with sIgA. Our findings suggest that sIgA may promote human lung inflammation and fibrosis by enhancing production of inflammatory or fibrogenic cytokines as well as extracellular matrix, inducing fibroblast differentiation into myofibroblasts and promoting human lung fibroblast proliferation. sIgA's enhancement of cytokine production may be due partially to its binding to CD71 or the secretory component.


Asunto(s)
Citocinas/biosíntesis , Inmunoglobulina A Secretora/farmacología , Pulmón/inmunología , Actinas/biosíntesis , Antígenos CD/fisiología , Células Cultivadas , Fibroblastos/inmunología , Humanos , Fibrosis Pulmonar Idiopática/etiología , Pulmón/citología , Receptores de Transferrina/fisiología
3.
Allergy ; 71(10): 1472-9, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27113353

RESUMEN

BACKGROUND: Omalizumab, a humanized anti-IgE monoclonal antibody, has demonstrated efficacy in patients with severe allergic asthma. However, treatment responses vary widely among individuals. Despite a lack of data, free serum IgE levels following omalizumab treatment have been proposed as a marker of treatment responsiveness. METHODS: In this prospective, observational study, we assessed the utility of biomarkers of type 2 inflammation in predicting omalizumab treatment responses, as determined by the absence of asthma exacerbation during the first year of treatment. Free serum IgE levels were monitored for 2 years to examine their association with baseline biomarker levels and the number of exacerbations. RESULTS: We enrolled thirty patients who had been treated with omalizumab for at least 1 year, of whom 27 were treated for 2 years. Baseline serum periostin levels and blood eosinophil counts were significantly higher in patients without exacerbations during the first year of treatment than in patients with exacerbations. Baseline serum periostin levels, but not eosinophil counts, were negatively associated with free serum IgE levels after 16 or 32 weeks of treatment. Reduced free serum IgE levels during treatment from those at baseline were associated with reduced exacerbation numbers at 2 years. In 14 patients who continued to have exacerbations during the first year of treatment, exacerbation numbers gradually and significantly decreased over the 2-year study period, with concurrent significant reductions in free serum IgE levels. CONCLUSION: Baseline serum periostin levels and serum free IgE levels during treatment follow-up may be useful in evaluating responses to omalizumab treatment.


Asunto(s)
Antiasmáticos/uso terapéutico , Asma/sangre , Asma/tratamiento farmacológico , Moléculas de Adhesión Celular/sangre , Inmunoglobulina E/sangre , Omalizumab/uso terapéutico , Adulto , Anciano , Antiasmáticos/farmacología , Asma/diagnóstico , Asma/inmunología , Biomarcadores , Progresión de la Enfermedad , Femenino , Humanos , Inmunoglobulina E/inmunología , Masculino , Persona de Mediana Edad , Omalizumab/farmacología , Curva ROC , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
4.
Clin Exp Allergy ; 44(5): 701-12, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24931597

RESUMEN

BACKGROUND: Chronic rhinosinusitis with nasal polyps is generally characterized by local Th2 inflammation and is categorized into two subtypes in Japan: eosinophilic chronic rhinosinusitis (similar to chronic rhinosinusitis with nasal polyps in western countries) and non-eosinophilic chronic rhinosinusitis (characterized by Th1-dominant inflammation). OBJECTIVE: To investigate local IgE production and class switch recombination to IgE in these two subtypes of chronic rhinosinusitis with nasal polyps. METHODS: The identity of IgE-positive cells was determined using double-immunofluorescent staining for IgE and cell-type-specific molecular markers. To investigate the local class switch recombination to IgE and IgE synthesis in the mucosa, we performed real-time polymerase chain reaction to examine the mRNA expression of Th2 cytokines and class-switch-related molecules, including IL-4, IL-5, IL-13, ε germline gene transcripts, IgE mature transcript, IgG mature transcript, RAG1, RAG2 and activation-induced cytidine deaminase in eosinophilic polyps, non-eosinophilic polyps and controls. RESULTS: The concentrations of total IgE and number of IgE-positive cells were significantly higher in the eosinophilic polyps compared with control and non-eosinophilic polyps. IgE-positive cells were predominantly mast cells in eosinophilic polyps and significantly correlated with the number of FcεR1-positive cells in the subepithelial layer. IL-5 and IL-13 mRNA and ε germline gene transcripts expression levels were significantly higher in eosinophilic polyps compared with control and non-eosinophilic polyps. In contrast, the number of plasma cells and the expression of IgG mature transcripts were increased in non-eosinophilic polyps compared with eosinophilic polyps. RAG2 mRNA was significantly increased in both eosinophilic and non-eosinophilic polyps compared with control mucosa. CONCLUSION AND CLINICAL RELEVANCE: The current study suggests local class switching to IgE, production of IgE and IgE localization to the surface of mast cells in eosinophilic chronic rhinosinusitis in the Japanese population. The difference in the IgE-related profiles between eosinophilic chronic rhinosinusitis and non-eosinophilic chronic rhinosinusitis suggests heterogeneity in the pathogenesis of chronic rhinosinusitis with nasal polyps.


Asunto(s)
Cambio de Clase de Inmunoglobulina/genética , Inmunoglobulina E/genética , Inmunoglobulina E/inmunología , Pólipos Nasales/etiología , Rinitis/complicaciones , Sinusitis/complicaciones , Adulto , Anciano , Subgrupos de Linfocitos B/inmunología , Subgrupos de Linfocitos B/metabolismo , Enfermedad Crónica , Citocinas/genética , Citocinas/metabolismo , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Eosinófilos/inmunología , Femenino , Regulación de la Expresión Génica , Proteínas de Homeodominio/genética , Proteínas de Homeodominio/metabolismo , Humanos , Cambio de Clase de Inmunoglobulina/inmunología , Inmunoglobulina E/metabolismo , Inmunoglobulina G/genética , Inmunoglobulina G/inmunología , Inflamación/inmunología , Inflamación/metabolismo , Recuento de Leucocitos , Masculino , Persona de Mediana Edad , Mucosa Nasal/inmunología , Mucosa Nasal/metabolismo , Mucosa Nasal/patología , Pólipos Nasales/diagnóstico , Proteínas Nucleares/genética , Proteínas Nucleares/metabolismo , Fenotipo , Receptores de IgE/genética , Receptores de IgE/metabolismo , Rinitis/diagnóstico , Sinusitis/diagnóstico
5.
Artículo en Inglés | MEDLINE | ID: mdl-18714538

RESUMEN

BACKGROUND: Basophils are an active participant in the pathogenesis of local inflammation in allergic diseases such as asthma, but it is not fully known how basophil activation is regulated in inflamed tissue. OBJECTIVE: In order to clarify the control mechanisms of basophil activation in chronic inflammation and at remodeling sites, we analyzed the effects of fibroblast-derived cytokines, stem cell factor (SCF), and insulin-like growth factor-I (IGF-I) on basophils. METHODS: The effects of SCF and IGF-I on degranulation and surface activation marker expression by basophils were assessed and compared. RESULTS: SCF enhanced human basophil histamine release elicited by some, but not all, secretagogues; degranulation in response to IgE- or FcepsilonRI-mediated stimulation and 12-o-tetradecanoyl-phorbol-13-acetate (TPA) was enhanced by SCF. SCF slightly enhanced ionophore A23187-induced histamine release by basophils from some donors, but it failed to affect the release elicited by monocyte chemoattractant protein-1 (MCP-1), formylmethionyl-leucyl-phenylalanine (FMLP) or C5a. The repertoire of secretagogues responsive to SCF was similar to that of IGF-I. Expression levels of both CD11b and CD69 markers were significantly enhanced by the combination of SCF and IGF-I. CONCLUSIONS: These results suggest that SCF and IGF-I may modify the activation of basophils in a similar and/or synergistic fashion. Interaction of basophils with these cytokines might be involved in the pathogenesis of local inflammation and the remodeling process in asthma.


Asunto(s)
Antígenos CD/metabolismo , Antígenos de Diferenciación de Linfocitos T/metabolismo , Basófilos/inmunología , Antígeno CD11b/metabolismo , Degranulación de la Célula/efectos de los fármacos , Liberación de Histamina/efectos de los fármacos , Factor I del Crecimiento Similar a la Insulina/farmacología , Factor de Células Madre/farmacología , Antígenos CD/inmunología , Antígenos de Diferenciación de Linfocitos T/inmunología , Basófilos/efectos de los fármacos , Basófilos/metabolismo , Antígeno CD11b/efectos de los fármacos , Antígeno CD11b/inmunología , Humanos , Factor I del Crecimiento Similar a la Insulina/inmunología , Lectinas Tipo C , Proteínas Recombinantes/farmacología , Factor de Células Madre/inmunología
6.
Am J Clin Nutr ; 66(2): 261-6, 1997 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9250103

RESUMEN

Dietary flavonoid intake has been reported to be inversely associated with the incidence of coronary artery disease. To clarify the possible role of tea flavonoids in the prevention of atherosclerosis, we investigated the effects of tea flavonoids on the susceptibility of low-density lipoprotein (LDL) to oxidative modification. In an in vitro study, catechins or theaflavins (25-400 mumol/L) were added to plasma and incubated for 3 h at 37 degrees C. Then, the LDL fraction was separated by ultracentrifugation. The oxidizability of LDL was estimated by measuring conjugated diene, thiobarbituric acid-reactive substances (TBARS), and lipid peroxides after cupric sulfate was added. TBARS and lipid peroxides in the supernates were also measured after incubation with macrophages. Catechins significantly (P < 0.01 by ANOVA) and dose-dependently prolonged the lag time before initiation of oxidation. Among the catechins, epigallocatechin gallate exerted the most marked effect, prolonging the oxidation lag time more than vitamin E at the same molar concentration. Theaflavins exerted stronger inhibitory effects than catechins. Macrophage-mediated LDL oxidation was also inhibited by adding these tea flavonoids to the plasma samples. In an in vivo study, 14 healthy volunteers consumed 750 mL black tea/d for 4 wk. After the subjects had consumed tea for 4 wk, the lag time before LDL oxidation was significantly (P < 0.01) prolonged from 54 to 62 min. This minor prolongation occurred despite much lower plasma flavonoids than were used in vitro. No significant change was observed in eight control volunteers. LDL exposed to tea flavonoids in vitro or in vivo reduced oxidizability. We speculate that tea flavonoids may have a role in ameliorating atherosclerosis.


Asunto(s)
Flavonoides/administración & dosificación , Lipoproteínas LDL/metabolismo , Té/química , Adulto , Arteriosclerosis/prevención & control , Humanos , Peróxidos Lipídicos/sangre , Masculino , Oxidación-Reducción , Valores de Referencia , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo
7.
Atherosclerosis ; 124(2): 157-69, 1996 Aug 02.
Artículo en Inglés | MEDLINE | ID: mdl-8830929

RESUMEN

We have investigated possible mechanisms by which n-3 fatty acid-enriched macrophages enhance the oxidation of low density lipoprotein (LDL), and the ability of antioxidant vitamins to prevent this. Macrophages were enriched with n-3 fatty acids (eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid) following incubation with fish oil. These macrophages produced large amount of TBARS in medium containing metals, and showed enhanced capacity to oxidize LDL (3-4 fold increase compared to control cells) and to accumulate the modified LDL. 5,8,11,14-eicosatetraynoic acid (ETYA, 15-lipoxygenase inhibitor) and superoxide dismutase (SOD) did not inhibit the enhanced capacity of n-3 fatty acid-enriched cells to oxidize LDL. However antioxidants, (vitamin E-enriched macrophages or vitamin C in the medium), inhibited this enhanced capacity. Medium conditioned by n-3 fatty acid-enriched cells had pro-oxidant effects on metal-initiated LDL oxidation. We conclude that n-3 fatty acid-enriched macrophages display increased oxidant capacity which is not inhibited by ETYA or SOD, and that antioxidant vitamins inhibit the enhanced capacity to oxidize LDL.


Asunto(s)
Antioxidantes/farmacología , Ácidos Grasos Omega-3/farmacología , Peroxidación de Lípido/fisiología , Lipoproteínas LDL/metabolismo , Macrófagos/metabolismo , Ácido 5,8,11,14-Eicosatetrainoico/farmacología , Arteriosclerosis/metabolismo , Arteriosclerosis/patología , Arteriosclerosis/prevención & control , Técnicas de Cultivo de Célula , Cromatografía de Gases , Humanos , Peroxidación de Lípido/efectos de los fármacos , Lipoproteínas LDL/efectos de los fármacos , Macrófagos/efectos de los fármacos , Macrófagos/patología , Superóxido Dismutasa/farmacología , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo , Ultracentrifugación
8.
Atherosclerosis ; 110(1): 77-86, 1994 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-7857373

RESUMEN

Vitamin E supplementation has been reported to protect low density lipoprotein (LDL) from copper-induced oxidation and macrophage-mediated oxidation. We investigated the effect of in vitro vitamin E enrichment of LDL on the accumulation of [3H]cholesteryl ester (CE)-LDL and stimulation of cholesteryl ester formation in J774 macrophages. Vitamin E supplementation prolonged lag time (2.9-fold) before the initiation of copper-induced LDL oxidation. LDL, preincubated with 5 microM copper or with macrophages in Ham's F10 medium, accumulated in macrophages much more than did native LDL. However, following vitamin E enrichment, LDL accumulation was significantly reduced following oxidative stress. Vitamin E-enriched LDL also reduced the stimulation of cholesteryl ester formation in macrophages. Moreover, vitamin E enrichment of macrophages reduced the ability of the cells to oxidize LDL. The present results indicate that vitamin E supplementation protects LDL against copper-induced and macrophage-mediated oxidation, inhibits oxidation-dependent accumulation of LDL in macrophages, and prevents stimulation of cholesteryl ester formation in macrophages. Additionally we have provided evidence that intra-cellular enrichment with vitamin E prevents oxidative modification of LDL by macrophages.


Asunto(s)
Ésteres del Colesterol/biosíntesis , Lipoproteínas LDL/metabolismo , Macrófagos/efectos de los fármacos , Vitamina E/farmacología , Arteriosclerosis/tratamiento farmacológico , Arteriosclerosis/metabolismo , Ésteres del Colesterol/metabolismo , Femenino , Humanos , Macrófagos/metabolismo , Masculino , Estrés Oxidativo , Vitamina E/uso terapéutico
9.
Atherosclerosis ; 139(1): 179-87, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9699906

RESUMEN

Previous reports have shown that administration of fibrates can reduce coronary events and also improve plasma lipid levels. Oxidative modification of low density lipoprotein has been implicated in the pathogenesis of atherosclerosis, and the resistance of low density lipoprotein (LDL) to in vitro oxidation has been found to be correlated with the extent of atherosclerosis. We performed a double-blind, placebo-controlled intervention trial to establish whether gemfibrozil could improve resistance of LDL to oxidation in patients with hyperlipidemia. Patients were randomly assigned to treatment with gemfibrozil (450 mg, twice a day, n = 10) or placebo (n = 9) for 8 weeks. Blood samples were obtained after an overnight (12 h) fast. Gemfibrozil administration significantly reduced total plasma cholesterol and triglyceride levels and changed the LDL from small, dense particles (pattern B, < or = 25.5 nm) to larger, more buoyant particles (pattern A, > 25.5 nm). Gemfibrozil significantly increased the lag time of LDL oxidation in vitro by 18.2% from 45.5 +/- 8.0 min at week 0 to 53.4 +/- 11.4 min at week 8, but did not change LDL vitamin E and beta-carotene concentrations. Surprisingly, gemfibrozil significantly decreased LDL lipid peroxides by -33.1% and increased the LDL vitamin E/lipid peroxide ratio by 67.6% from 1.3 +/- 0.5 at week 0 to 2.1 +/- 0.9 at week 8. These results demonstrate that gemfibrozil treatment can render LDL less susceptible to oxidative modification while reducing plasma cholesterol and triglyceride and improving LDL subclass pattern. This antioxidative effect of gemfibrozil on LDL may be one of the factors which could delay the progression of atherosclerosis.


Asunto(s)
Gemfibrozilo/uso terapéutico , Hipolipemiantes/uso terapéutico , Lipoproteínas LDL/metabolismo , Estrés Oxidativo , Adulto , Anciano , Apolipoproteínas/sangre , Arteriosclerosis/tratamiento farmacológico , Arteriosclerosis/metabolismo , Método Doble Ciego , Ácidos Grasos no Esterificados/sangre , Femenino , Humanos , Hiperlipidemias/tratamiento farmacológico , Hiperlipidemias/metabolismo , Peróxidos Lipídicos/sangre , Lípidos/sangre , Lipoproteínas LDL/química , Masculino , Persona de Mediana Edad , Oxidación-Reducción , Vitamina E/sangre
10.
Am J Cardiol ; 84(10): 1272-4, A9, 1999 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-10569346

RESUMEN

This study examined the effects of fat- plus sucrose-rich meals on endothelium-dependent flow-mediated vasodilation in diabetic patients. Flow-mediated vasodilation in the postprandial state decreased significantly, and the decrease correlated inversely with the magnitude of postprandial hyperglycemia, suggesting that endothelial function in diabetic patients becomes impaired postprandially.


Asunto(s)
Diabetes Mellitus Tipo 2/fisiopatología , Endotelio Vascular/fisiopatología , Periodo Posprandial/fisiología , Vasodilatación/fisiología , Adulto , Diabetes Mellitus Tipo 2/sangre , Femenino , Hemoglobina Glucada/análisis , Hemodinámica , Humanos , Masculino , Persona de Mediana Edad
11.
Biochem Pharmacol ; 58(11): 1695-703, 1999 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-10571243

RESUMEN

Dietary flavonoid intake has been reported to be inversely related to mortality from coronary heart disease, and the anti-atherosclerotic effect of flavonoids is considered to be due probably to their antioxidant properties. Oxidation of low density lipoprotein (LDL) has been reported to be induced by the constituent cells of the arterial wall. Accordingly, we examined the effect of pretreatment with tea flavonoids, such as theaflavin digallate, on the ability of cells to oxidize LDL. Theaflavin digallate pretreatment of macrophages or endothelial cells reduced cell-mediated LDL oxidation in a concentration- (0-400 microM) and time- (0-4 hr) dependent manner. This inhibitory effect of flavonoids on cell-mediated LDL oxidation was in the order of theaflavin digallate > theaflavin > or = epigallocatechin gallate > epigallocatechin > gallic acid. Further, we investigated the mechanisms by which flavonoids inhibited cell-mediated LDL oxidation using macrophages and theaflavin digallate. Theaflavin digallate pretreatment decreased superoxide production of macrophages and chelated iron ions significantly. These results suggest that tea flavonoids attenuate the ability of the cell to oxidize LDL, probably by reducing superoxide production in cells and chelating iron ions.


Asunto(s)
Biflavonoides , Flavonoides/farmacología , Lipoproteínas LDL/metabolismo , Macrófagos/efectos de los fármacos , Té/química , Animales , Antioxidantes/farmacología , Catequina , Supervivencia Celular/efectos de los fármacos , Endotelio/efectos de los fármacos , Endotelio/metabolismo , Ácido Gálico/análogos & derivados , Ácido Gálico/farmacología , Técnicas In Vitro , Hierro/metabolismo , Macrófagos/metabolismo , Masculino , Ratones , Ratones Endogámicos ICR , Oxidación-Reducción/efectos de los fármacos , Superóxidos/metabolismo
12.
Environ Health Perspect ; 108(2): 105-8, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10656849

RESUMEN

Both active and passive smoking are regarded as risk factors for various diseases. To clarify the effects of active and passive smoking on plasma vitamin C levels and lipid peroxidation status, we examined the plasma levels of ascorbic acid (AA), its redox status [ratio of dehydroascorbate (DHAA) to total AA], the levels of thiobarbiturate reactive substance (TBARS), and the levels of lipid peroxides (LPO) in smokers, nonsmokers, and nonsmokers regularly exposed to environmental cigarette smoke (passive smokers). The study population consisted of 149 healthy males: 75 active smokers (consumption of > 15 cigarettes/day for more than 5 years), 36 passive smokers (more than 10 hr/week exposure to environmental cigarette smoke), and 38 nonsmokers (no cigarette smoke exposure). There were no significant differences in plasma TBARS and LPO levels among the three groups. Plasma levels of AA, the reduced form of vitamin C, were significantly lower in active smokers than in the combined nonsmoking groups (7.2 +/- 3.5 and 8.4 +/- 3.4 microg/mL, respectively; p < 0.05). Although no significant differences were found in plasma DHAA levels among the three groups, the ratios of DHAA to total AA were significantly higher in active and passive smokers than nonexposed nonsmokers (11.2, 10.3, and 7.1%, respectively; p < 0.05). These results indicate that passive smoking, as well as direct inhalation of cigarette smoke, affects the redox status of plasma AA. In passive smokers, the altered redox status of plasma AA suggests an oxidative stress.


Asunto(s)
Ácido Ascórbico/sangre , Peróxidos Lipídicos/sangre , Fumar/sangre , Sustancias Reactivas al Ácido Tiobarbitúrico/análisis , Contaminación por Humo de Tabaco , Adulto , Estudios de Casos y Controles , Humanos , Peroxidación de Lípido , Masculino , Persona de Mediana Edad
13.
J Appl Physiol (1985) ; 67(6): 2205-11, 1989 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2606825

RESUMEN

In six open-chest dogs, electrocardiogram- (ECG) controlled pulmonary arterial occlusion was performed during the control period and during the infusions of serotonin and histamine. A temporal series of instantaneous pulmonary capillary pressure and the longitudinal distributions of vascular resistance and compliance were evaluated in the intact left lower lung lobe. In the control period, we found a significant phasic variation of pulmonary capillary pressure (Pc) with the cardiac cycle. The ratio of arterial to venous resistances (Ra/Rv) was 6:4, and the ratio of arterial to capillary compliances (Ca/Cc) was 1:11. During the infusions of serotonin and histamine, Pc showed similar phasic variations, despite significant hemodynamic changes induced by these agents. Serotonin predominantly increased Ra, whereas histamine predominantly increased Rv. The ratio of Rv to the total resistance decreased significantly from 0.42 to 0.32 during the infusion of serotonin and increased significantly to 0.62 during the infusion of histamine. The data suggest that phasic Pc determined by ECG-controlled arterial occlusion reflects the pulsatility in the pulmonary microvascular bed under control conditions and after alterations of the pulmonary vascular resistance by serotonin and histamine.


Asunto(s)
Presión Sanguínea/fisiología , Arteria Pulmonar/fisiología , Circulación Pulmonar/fisiología , Animales , Perros , Electrocardiografía , Histamina/farmacología , Ligadura , Circulación Pulmonar/efectos de los fármacos , Serotonina/farmacología , Resistencia Vascular
14.
Hypertens Res ; 18(1): 47-53, 1995 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-7584910

RESUMEN

Twelve adults (age 32-61 years) with essential hypertension were recruited from the outpatient clinics of National Defense Medical College hospital to serve as subjects in the present study. They were treated with nilvadipine, a Ca-antagonist, 4 mg b.i.d. for 4 weeks. LDL samples were isolated by ultracentrifugation at the beginning (week 0) and at the end (week 4) of the treatment regimen. The formation of conjugated dienes was measured by incubating 100 micrograms of LDL protein with 2 mumol CuSO4 in 2 ml phosphate buffered saline (PBS). There were no significant differences between lipids levels, composition and anti-oxidant levels of LDL at weeks 0 and 4. The lag time of LDL oxidation was 71.1 +/- 11.3 min at week 0 and 81.3 +/- 13.2 min at week 4 (p < 0.05). In vitro studies of LDL oxidation, evaluated by thiobarbituric acid reactive substances (TBARS) and by agarose electrophoretic mobility, indicated that nilvadipine inhibited the oxidative modification of LDL while amlodipine, used as control, did not. Nilvadipine, a lipophilic Ca-antagonist, significantly prolonged the lag time of conjugated diene formation of LDL by 12.6% but amlodipine, a hydrophilic Ca-antagonist, had no major effect on LDL oxidation. These results suggest that Ca-antagonists are effective for the prevention of atherosclerosis but the effect is dependent upon the lipophilicity of the drugs.


Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Hipertensión/sangre , Lipoproteínas LDL/sangre , Nifedipino/análogos & derivados , Adulto , Amlodipino/química , Amlodipino/farmacología , Apolipoproteínas/sangre , Bloqueadores de los Canales de Calcio/química , Bloqueadores de los Canales de Calcio/uso terapéutico , Electroforesis en Gel de Agar , Ácidos Grasos/sangre , Femenino , Humanos , Hipertensión/tratamiento farmacológico , Técnicas In Vitro , Lípidos/sangre , Lipoproteínas LDL/química , Masculino , Persona de Mediana Edad , Nifedipino/química , Nifedipino/farmacología , Nifedipino/uso terapéutico , Oxidación-Reducción , Sustancias Reactivas al Ácido Tiobarbitúrico
15.
Clin Ther ; 17(3): 379-89, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7585842

RESUMEN

In this pilot study, 12 patients (6 men, 6 postmenopausal women) with hypercholesterolemia were treated with low-dose (5 mg/d) simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 4 weeks. Low-density lipoprotein (LDL) samples were isolated at the beginning (week 0) and at the end (week 4) of the treatment regimen. Simvastatin caused significant decreases of total cholesterol (-18.1%), LDL cholesterol (-27.6%), and apolipoprotein B (-21.8%), and significantly reduced total cholesterol, free cholesterol, cholesterol esters, phospholipids, and protein in LDL without significantly changing the component ratios and fatty acid levels of LDL. However, simvastatin therapy had no major effects on either antioxidant levels in LDL or the oxidative susceptibility of LDL. We conclude that low-dose simvastatin significantly reduces LDL cholesterol levels without increasing the oxidative susceptibility of LDL or decreasing the antioxidant levels of LDL, and thus may reduce the risk of coronary artery disease.


Asunto(s)
Anticolesterolemiantes/uso terapéutico , Antioxidantes/metabolismo , Colesterol/sangre , Hipercolesterolemia/tratamiento farmacológico , Lipoproteínas LDL/sangre , Lovastatina/análogos & derivados , Adulto , Anciano , Anticolesterolemiantes/administración & dosificación , Femenino , Humanos , Hipercolesterolemia/sangre , Lovastatina/administración & dosificación , Lovastatina/uso terapéutico , Masculino , Persona de Mediana Edad , Oxidación-Reducción , Proyectos Piloto , Simvastatina
16.
Lipids ; 33(12): 1169-75, 1998 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9930402

RESUMEN

The effects of vitamin E on cholesteryl ester (CE) metabolism in J774 cells were examined. Pretreatment of J774 cells with vitamin E at concentrations above 50 microM significantly decreased acetylated low density lipoprotein (LDL)-induced incorporation of [14C]oleate into CE in cells in a dose-dependent manner. This was partly due to vitamin E also significantly inhibiting the uptake of [3H]CE-labeled acetylated LDL by J774 cells. A trend existed toward suppression of acyl-CoA:cholesterol acyltransferase (ACAT) activity in the cell lysate at high vitamin E concentration, but there was no effect on hydrolysis of CE. These data indicate that vitamin E reduces the uptake of modified LDL and suppresses ACAT activity, resulting in less cholesterol esterification in macrophages: a novel mechanism underlying the antiatherogenic properties of vitamin E.


Asunto(s)
Colesterol/metabolismo , Lipoproteínas LDL/metabolismo , Macrófagos/efectos de los fármacos , Vitamina E/farmacología , Animales , Línea Celular , Ésteres del Colesterol/metabolismo , Esterificación , Humanos , Hidrólisis , Macrófagos/enzimología , Macrófagos/metabolismo , Masculino , Esterol O-Aciltransferasa/metabolismo
17.
Biofactors ; 7(1-2): 51-4, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9523028

RESUMEN

Supplementation of LDL with vitamin E is thought to protect LDL from oxidative modification and prevent the development of atherosclerosis. Large epidemiological studies have revealed that vitamin E levels in plasma are inversely correlated to the incidence of coronary heart disease. Double-blind placebo-controlled trials have reported that supplementation with vitamin E decreases the incidence of coronary events in coronary heart disease (CHD) patients. However, it is not clear how high a dose of vitamin E is needed to prevent formation of atherosclerosis. In animal studies, a diet containing 0.125% vitamin E increased its levels in plasma two-fold and prevented formation of early atherosclerotic lesions in the thoracic aorta of hypercholesterolemic rabbits. Dose-response studies in humans have reported that 400 IU/day vitamin E increased its levels in plasma two-fold and prolonged the lag time before LDL oxidation. It has been reported that oxidizability of LDL was correlated to the atherosclerotic score of coronary angiography in CHD patients. About 400 IU/day vitamin E, which increases its levels two-fold and prolongs sufficiently the lag time before LDL oxidation, might be beneficial in decreasing the individual risk of CHD.


Asunto(s)
Arteriosclerosis/prevención & control , Peroxidación de Lípido/efectos de los fármacos , Lipoproteínas LDL/metabolismo , Vitamina E/administración & dosificación , Animales , Enfermedad Coronaria/sangre , Enfermedad Coronaria/mortalidad , Enfermedad Coronaria/prevención & control , Humanos , Conejos , Vitamina E/sangre , Vitamina E/uso terapéutico
18.
Heart Lung ; 29(1): 56-9, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10636958

RESUMEN

OBJECTIVE: To demonstrate combining unheated bubble-through humidifier with a heat-moisture exchanger filter for the purpose of decreasing condensate contamination in mechanical ventilator tubing. DESIGN: Single-case, pretest and posttest. SETTING: University-affiliated and nonprofit hospital. PATIENT: A 32-year-old man with Pickwickian syndrome and pneumonia caused by Pseudomonas aeruginosa received mechanical ventilation for 14 days. METHODS: Ventilator tubing was cultured in two 24-hour trials, using a pretest and posttest design, to assess tubing bacterial contamination during use of 2 humidification methods. In the first trial, a traditional heated bubble-through humidifier (HBH) was used for 24 hours. Before the start of the second trial, the "wet" tubing and the heated bubble-through humidifier were removed and replaced with clean equipment through the use of aseptic technique. The bubble-through humidifier was placed on the "cold," or unheated mode, and a heat-moisture exchanger filter was attached to the Y-connector of the ventilator tubing. RESULTS: The heated bubble-through humidifier method revealed contamination of the ventilator tubing in 3 places with the patient's strain of P aeruginosa in addition to copious water condensate. The unheated bubble-through humidifier/heat moisture exchanger filter method demonstrated no bacterial contamination or condensate in the tubing. CONCLUSION: It can be inferred that the humidification method using the combination of an unheated bubble-through humidifier and a heat moisture exchanger filter has the potential benefit of preventing "reseeding" of the patient's airway with contaminated condensate.


Asunto(s)
Contaminación de Equipos/prevención & control , Humedad , Respiración Artificial , Adulto , Humanos , Masculino , Pseudomonas aeruginosa/aislamiento & purificación , Insuficiencia Respiratoria/terapia
19.
J Nutr Sci Vitaminol (Tokyo) ; 47(3): 213-21, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11575576

RESUMEN

Effects of tomato juice supplementation on the carotenoid concentration in lipoprotein fractions and the oxidative susceptibility of LDL were investigated in 31 healthy Japanese female students. These subjects were randomized to one of three treatment groups; Control, Low and High. The Control, Low and High groups consumed 480 g of a control drink, 160 g of tomato juice plus 320 g of the control drink, and 480 g of tomato juice, providing 0, 15 and 45 mg of lycopene, respectively, for one menstrual cycle. The ingestion of tomato juice, rich in lycopene but having little beta-carotene, increased both lycopene and beta-carotene. Sixty-nine percent of lycopene in plasma was distributed in the LDL fraction and 24% in the HDL fraction. In the Low group, the lycopene concentration increased 160% each in the VLDL+IDL, LDL and HDL fractions (p<0.01). In the High group, the lycopene concentration increased 270% each in the VLDL+IDL and LDL fractions, and 330% in the HDL fraction (p<0.01). Beta-carotene also increased 120% and 180% in LDL fractions of the Low and the High groups, respectively. Despite these carotenoid increases in LDL, the lag time before oxidation was not prolonged as compared with that of the Control group. The propagation rate decreased significantly after consumption in the High group. Multiple regression analysis showed a positive correlation between lag time changes and changes in the alpha-tocopherol concentration per triglyceride in LDL, and a negative correlation between propagation rate changes and changes in the lycopene concentration per phospholipid in LDL. These data suggest that alpha-tocopherol is a major determinant in protecting LDL from oxidation, while lycopene from tomato juice supplementaion may contribute to protect phospholipid in LDI, from oxidation. Thus, oral intake of lycopene might be beneficial for ameliorating atherosclerosis.


Asunto(s)
Antioxidantes/metabolismo , Bebidas , Carotenoides/metabolismo , Lipoproteínas LDL/metabolismo , Solanum lycopersicum , beta Caroteno/metabolismo , Adulto , Arteriosclerosis/prevención & control , Carotenoides/análisis , Carotenoides/sangre , Carotenoides/uso terapéutico , Femenino , Humanos , Lipoproteínas/química , Licopeno , Solanum lycopersicum/química , Oxidación-Reducción , beta Caroteno/sangre , beta Caroteno/uso terapéutico
20.
J Nutr Sci Vitaminol (Tokyo) ; 44(1): 113-27, 1998 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9591239

RESUMEN

To elucidate the effects of soybean protein and casein on postprandial lipemia, oral fat load tests were performed before and 3 weeks after the administration of soy protein isolate (SPI) and casein supplement to normolipidemic men. Eleven normolipidemic male subjects on otherwise identical controlled diets were assigned to either a 20 g/d soy protein isolate (SPI) dietary supplement or a casein dietary supplement for three weeks in a crossover design. Fat load tests with 40 g/m2 of bovine milk fat were carried out before and after 3 weeks on the experimental dietary supplements. Fasting plasma concentrations of lipids and apolipoproteins were not significantly different from baseline levels before or after the administration of SPI or casein supplemented diets. Neither SPI nor casein supplement affected the fasting plasma concentrations of lipids and apolipoproteins. The areas under the incremental curve (AUIC) of triglyceride (TG) and remnant-like particles triglyceride (RLP-TG) after both experimental diets were not significantly different from those before the experimental diets. However, the AUIC of remnant-like particles cholesterol (RLP-C) showed a tendency (p = 0.07) to decrease after administration of the diet supplemented with SPI than before the diet. The AUIC of RLP-C was significantly (p < 0.05) lower after the diet supplemented with SPI than after administration of the diet supplemented with casein. These results suggest that 3 weeks of 20 g/d SPI dietary supplement favorably affects the postprandial remnant lipoprotein response as compared to the casein dietary supplement.


Asunto(s)
Caseínas/farmacología , Grasas de la Dieta/administración & dosificación , Proteínas en la Dieta/farmacología , Lípidos/sangre , Proteínas de Soja/farmacología , Adulto , Animales , Apolipoproteínas/sangre , Apolipoproteínas E/sangre , Caseínas/administración & dosificación , Colesterol/sangre , Proteínas en la Dieta/administración & dosificación , Ingestión de Energía , Humanos , Lipoproteínas HDL/sangre , Lipoproteínas LDL/sangre , Masculino , Leche/química , Fenotipo , Proteínas de Soja/administración & dosificación , Triglicéridos/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA